Hematologic Malignancy
Transformed T-Cell Non-Hodgkin Lymphoma
CI-CAN-00006979Explore in graph →
Hematologic1 active trials
- NCIt
- C216071
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006979Explore in graph →
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04774068 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | completed | Phase 1 | 5 | Walter HanelOTHER | 1 | Jan 17, 2025 |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials